Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666991 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 study of Peritoneal Neoplasms, sponsored by CritiTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT00666991 is a Phase 1 study of Peritoneal Neoplasms that has completed, run by CritiTech. The registered enrollment target is 22 participants, below the 436-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00666991, a Phase 1 study of Peritoneal Neoplasms, has completed, sponsored by CritiTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
Conditions Studied
Interventions
- DRUG nanoparticulate paclitaxel
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
- Cancer Center of Kansas - Wichita
Oklahoma
- Peggy and Charles Stephenson Oklahoma Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666991
The ClinicalTrials.gov registry entry for NCT00666991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 436-participant average among 14 other Peritoneal Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is CritiTech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peritoneal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which nanoparticulate paclitaxel is the first listed.
NCT00666991 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00666991 about?
NCT00666991 is a clinical study titled "Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers". The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
What is the current status of trial NCT00666991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-07. Estimated completion is 2013-05.
What conditions does trial NCT00666991 study?
This clinical trial studies the following conditions: Peritoneal Neoplasms.
What interventions are being tested in trial NCT00666991?
The interventions under investigation include: nanoparticulate paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00666991?
This trial is sponsored by CritiTech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666991 being conducted?
This trial has 3 study locations across Kansas, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.